[go: up one dir, main page]

NO20080202L - Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer - Google Patents

Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer

Info

Publication number
NO20080202L
NO20080202L NO20080202A NO20080202A NO20080202L NO 20080202 L NO20080202 L NO 20080202L NO 20080202 A NO20080202 A NO 20080202A NO 20080202 A NO20080202 A NO 20080202A NO 20080202 L NO20080202 L NO 20080202L
Authority
NO
Norway
Prior art keywords
nanoparticulate
clopidogrel
aspirin
particles
nanoparticulate clopidogrel
Prior art date
Application number
NO20080202A
Other languages
English (en)
Inventor
Scott Jenkins
Gary G Liversidge
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20080202L publication Critical patent/NO20080202L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J1/00—Details of electrodes, of magnetic control means, of screens, or of the mounting or spacing thereof, common to two or more basic types of discharge tubes or lamps
    • H01J1/02—Main electrodes
    • H01J1/30—Cold cathodes, e.g. field-emissive cathode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse angår sammensetninger som innbefatter en nanopartikulær klopidogrel- og aspirinkombinasjon, eller salter eller derivater derav, som har forbedret klopidogrel biotilgjengelighet. De nanopartikulære klopidogrelpartiklene, og eventuelt de nanopartikulære aspirinpartiklene, i sammensetningen har en effektiv gjennomsnittlig partikkelstørrelse på mindre enn ca. 2000 nm og er anvendelige når det gjelder å hindre og behandle patologier indusert av blodplateaggregering. Klopidogrelog aspirinpartiklene kan også formuleres som et kontrollert frigivelse polymerisk belegg eller matrikslegemiddelleveringssystem.
NO20080202A 2005-06-13 2008-01-11 Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer NO20080202L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68993005P 2005-06-13 2005-06-13
PCT/US2006/022811 WO2006138214A1 (en) 2005-06-13 2006-06-12 Nanoparticulate clopidogrel and aspirin combination formulations

Publications (1)

Publication Number Publication Date
NO20080202L true NO20080202L (no) 2008-03-12

Family

ID=37103356

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080202A NO20080202L (no) 2005-06-13 2008-01-11 Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer

Country Status (14)

Country Link
US (1) US20070003615A1 (no)
EP (1) EP1898911A1 (no)
JP (1) JP2008543843A (no)
KR (1) KR20080016952A (no)
CN (1) CN101237868A (no)
AU (1) AU2006259606A1 (no)
BR (1) BRPI0611626A2 (no)
CA (1) CA2611741A1 (no)
EA (1) EA200800041A1 (no)
IL (1) IL188079A0 (no)
MX (1) MX2007015882A (no)
NO (1) NO20080202L (no)
WO (1) WO2006138214A1 (no)
ZA (1) ZA200800050B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2236847C2 (ru) * 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Композиции в виде множества частиц с модифицированным высвобождением
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
US20080069870A1 (en) * 2005-04-12 2008-03-20 Elan Corporation Pic Controlled Release Compositions Comprising a Cephalosporin for the Treatment of a Bacterial Infection
EP1937218A2 (en) * 2005-05-23 2008-07-02 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
KR20090015994A (ko) * 2006-05-30 2009-02-12 엘란 파마 인터내셔널 리미티드 나노입자형 포사코나졸 제제
EP2049084A2 (en) * 2006-07-10 2009-04-22 Elan Pharma International Limited Nanoparticulate sorafenib formulations
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
CA2684985A1 (en) * 2007-03-16 2008-09-25 Elan Pharma International Limited Combination of a narcotic and a non-narcotic analgesic
RU2009140792A (ru) * 2007-04-09 2011-05-20 Юсв Лимитед (In) Новые стабильные фармацевтические композиции клопидогрель бисульфата и способ их получения
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US8377989B2 (en) * 2007-10-17 2013-02-19 Todd F. Ovokaitys Room temperature stable non-crystalline aspirin and method for the preparation thereof
WO2009052246A1 (en) * 2007-10-17 2009-04-23 Ovokaitys, Todd, F. Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
RU2010144554A (ru) * 2008-04-01 2012-05-10 Астеллас Фарма Инк. (Jp) Средство для предотвращения и/или лечения сосудистых заболеваний
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
KR101912709B1 (ko) 2009-05-13 2018-10-30 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
CN101695496A (zh) * 2009-10-15 2010-04-21 苏春华 一种含有三氟柳和氯吡格雷的药物组合物
CN101703513B (zh) * 2009-11-10 2014-04-23 沈阳药科大学 阿司匹林和氯吡格雷或其药学上可接受的盐的复方缓释制剂
EP2633857B1 (en) * 2009-12-23 2015-08-12 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
CN101919890A (zh) * 2010-08-18 2010-12-22 徐震 一种含氯吡格雷硫酸氢盐的片剂及其制备方法
NZ606903A (en) * 2010-08-26 2015-05-29 Ipca Lab Ltd Methods for the treatment or prophylaxis of thrombosis or embolism
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
CN103917544A (zh) * 2011-09-14 2014-07-09 波曾公司 氯吡格雷的分阶段给药
KR101675501B1 (ko) 2011-11-02 2016-11-14 한국유나이티드제약 주식회사 클로피도그렐 및 아스피린의 복합제제
CA2858522A1 (en) * 2011-12-09 2013-06-13 Wockhardt Limited Methods for treating cardiovascular disorder
WO2013133620A1 (en) * 2012-03-09 2013-09-12 Yuhan Corporation Pharmaceutical composition comprising clopidogrel and aspirin and process for preparing the same
KR101502588B1 (ko) * 2013-05-01 2015-03-16 한국유나이티드제약 주식회사 클로피도그렐 및 아스피린의 복합제제
DK3107548T3 (da) * 2014-02-20 2022-07-18 Otitopic Inc Tørpulverformuleringer til inhalation
CN104971070A (zh) * 2014-04-04 2015-10-14 北京大学 替格瑞洛口服纳米组合物
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2015187974A1 (en) 2014-06-06 2015-12-10 Ovokaitys Todd Frank Methods and compositions for increasing the bioactivity of nutrients
CN107072947A (zh) * 2014-07-31 2017-08-18 奥迪托皮克股份有限公司 用于吸入的干粉制剂
KR101764785B1 (ko) * 2015-05-29 2017-08-07 한국유나이티드제약 주식회사 약제학적 복합제제
WO2017037741A1 (en) * 2015-09-02 2017-03-09 Sun Pharmaceutical Industries Ltd Compact solid dosage form of aspirin and clopidogrel
CN105769882B (zh) * 2016-03-14 2019-02-22 北京赛德维康医药研究院 一种抑制血栓形成的药物组合物及其用途
KR102024699B1 (ko) * 2016-03-16 2019-09-26 한국유나이티드제약 주식회사 클로피도그렐 및 아스피린을 포함하는 복합제제
CN106619549B (zh) * 2017-01-03 2019-12-06 江苏吴中医药集团有限公司苏州制药厂 一种替格瑞洛与阿司匹林复合片剂及其制备方法
CN115919780A (zh) * 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
EP4259162A4 (en) 2020-12-08 2024-11-06 Todd F. Ovokaitys METHODS AND SYSTEMS FOR ENHANCED STEM CELL PRODUCTION

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520009A (en) * 1983-11-28 1985-05-28 Verex Laboratories, Inc. Sustained released aspirin formulation
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5157030A (en) * 1989-08-25 1992-10-20 Alexander Galat Rapidly soluble aspirin compositions and method
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
EP0593627A1 (en) * 1991-07-05 1994-04-27 The University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5518178A (en) * 1994-03-02 1996-05-21 Sermatech International Inc. Thermal spray nozzle method for producing rough thermal spray coatings and coatings produced
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
EP0810853B1 (en) * 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5723453A (en) * 1995-11-13 1998-03-03 Health Corporation Stabilized, water-soluble aspirin composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
JPH10303288A (ja) * 1997-04-26 1998-11-13 Anelva Corp プラズマ処理装置用基板ホルダー
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
CA2350706A1 (en) * 1998-11-13 2000-05-25 Elan Pharma International Limited Drug delivery systems and methods
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
FR2792836B3 (fr) * 1999-04-30 2001-07-27 Sanofi Sa Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel
EP1185371B2 (en) * 1999-06-01 2008-11-12 Elan Pharma International Limited Small-scale mill and method thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
USRE38576E1 (en) * 2000-03-03 2004-08-31 Natalie Blahut Stabilized aspirin compositions and method of preparation for oral and topical use
CA2406696C (en) * 2000-04-26 2009-06-30 Elan Pharma International Limited Apparatus for sanitary wet milling
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
IN191030B (no) * 2001-01-24 2003-09-13 Cadila Healthcare Ltd
CA2449490C (en) * 2001-06-05 2010-10-05 Elan Pharma International Limited System and method for milling materials
US20030087308A1 (en) * 2001-06-22 2003-05-08 Elan Pharma International Limited Method for high through put screening using a small scale mill or microfluidics
JP4464129B2 (ja) * 2001-09-19 2010-05-19 エラン ファーマ インターナショナル，リミティド ナノ粒子インスリン製剤
CA2463495C (en) * 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
DK1471887T3 (da) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
EP1490025B1 (en) * 2002-03-20 2008-02-13 Elan Pharma International Limited Nanoparticulate compositions of map kinase inhibitors
AU2003230691A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
JP2005529911A (ja) * 2002-05-06 2005-10-06 エラン ファーマ インターナショナル，リミティド ナノ粒子ナイスタチン製剤
JP2005531606A (ja) * 2002-06-10 2005-10-20 エラン ファーマ インターナショナル，リミティド ナノ粒子ステロール製剤およびステロールの組合せ
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
IL166593A0 (en) * 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
US6800759B2 (en) * 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
DK1553927T3 (da) * 2002-09-11 2011-01-31 Elan Pharma Int Ltd Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
AU2003268380A1 (en) * 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
CA2504610C (en) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
WO2004074215A1 (en) * 2003-02-03 2004-09-02 Sunil Sadanand Nadkarni Process for preparation of clopidogrel, its salts and pharmaceutical compositions
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US6858734B2 (en) * 2003-04-23 2005-02-22 Rhodia Pharma Solutions Inc. Preparation of (S)-Clopidogrel and related compounds
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US20050147664A1 (en) * 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery

Also Published As

Publication number Publication date
EP1898911A1 (en) 2008-03-19
WO2006138214A1 (en) 2006-12-28
US20070003615A1 (en) 2007-01-04
CA2611741A1 (en) 2006-12-28
JP2008543843A (ja) 2008-12-04
EA200800041A1 (ru) 2008-04-28
CN101237868A (zh) 2008-08-06
BRPI0611626A2 (pt) 2010-09-21
IL188079A0 (en) 2011-08-01
ZA200800050B (en) 2008-12-31
AU2006259606A1 (en) 2006-12-28
KR20080016952A (ko) 2008-02-22
MX2007015882A (es) 2008-03-04

Similar Documents

Publication Publication Date Title
NO20080202L (no) Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer
NO20076215L (no) Nanopartikulaere clopidogrelformuleringer
NO20076692L (no) Nanopartikulaere acetaminofenformuleringer
AR063940A1 (es) Formulaciones de posaconazol nanoparticulado
WO2008008733A3 (en) Nanoparticulate sorafenib formulations
WO2012001074A3 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
WO2008092006A3 (en) Antimicrobial compositions
EA200701997A1 (ru) Композиция из наночастиц бисфосфоната
WO2008109142A3 (en) Pirna and uses related thereto
WO2007119601A3 (en) Nanoparticles comprising a pdgf receptor tyrosine kinase inhibitor
BRPI0518772A2 (pt) formulaÇÕes de benzotiofeno em nanopartÍcula
WO2010125323A8 (en) Biocidal composition
WO2007008537A3 (en) Nanoparticulate clarithromycin formulations
HK1209371A1 (en) Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
NO20076628L (no) Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser
EA201390979A1 (ru) Композиции бензимидазолов с модифицированным высвобождением
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
BR112015014092A2 (pt) administração oral transmucosal de acetato de glatirâmer
UA93530C2 (ru) Композиция c пролонгированным высвобождением активного вещества, способ ee получения и применения
WO2008030209A3 (en) Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
WO2007146943A3 (en) Nanoparticulate kinase inhibitor formulations
ATE446742T1 (de) Nanopartikuläre ebastinformulierungen
WO2006138421A3 (en) Nanoparticulate azelnidipine formulations
GB2442366A (en) Nanoparticulate and controlled release compositions comprising prostaglandin derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application